Also, semaglutide was never compared with pioglitazone, which, along with GLP-1 Ras, is the preferred treatment for T2D with NAFLD, according to the recent American Diabetes Association (ADA) [19]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.